Q-omics provides the consensus-scored MIR1179 profile across patient tissues and cancer cell-line models. MIR1179 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, MIR1179 is differentially expressed in 1, with the highest sampling consensus in THCA. Additionally, MIR1179 RNA expression shows 11,462 significant gene co-expression associations, with the highest sampling consensus in COAD. Together, these results highlight STAD, THCA, and COAD as cancer lineages where MIR1179 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR1179 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR1179 survival associations across molecular data types. MIR1179 RNA expression shows survival associations in the most cancer types (13), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR1179 RNA expression–survival associations across cancer types. High MIR1179 expression shows unfavorable associations in STAD, TGCT, THCA, CESC, LIHC and SKCM. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for MIR1179 RNA expression.
This table summarizes MIR1179 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR1179. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR1179 shows lower tumor expression in THCA. The THCA box plot shows higher MIR1179 RNA expression in normal versus tumor tissue (log2 FC = −0.582, t-test p < 0.001).
This table shows molecular features associated with MIR1179 in patient tissues and cancer cell lines. In patient samples, MIR1179 shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set.
